Clinical trial NCT05203744 - References

Prophylaxis — Escalating Monthly Doses of Tafenoquine in Healthy Volunteers

Citation(s)

•   Ackert J, Mohamed K, Slakter JS, El-Harazi S, Berni A, Gevorkyan H, Hardaker E, Hussaini A, Jones SW, Koh GCKW, Patel J, Rasmussen S, Kelly DS, Barañano DE, Thompson JT, Warren KA, Sergott RC, Tonkyn J, Wolstenholme A, Coleman H, Yuan A, Duparc S, Green JA
  Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers. Drug Saf. 2019 Sep;42(9):1103-1114. doi: 10.1007/s40264-019-00839-w.
•   Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, Sreng S, Drury E, Stalker J, Miotto O, Fairhurst RM, Kwiatkowski DP
  Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018 Mar;18(3):337-345. doi: 10.1016/S1473-3099(18)30068-9. Epub 2018 Feb 2.
•   Anh CX, Chavchich M, Birrell GW, Van Breda K, Travers T, Rowcliffe K, Lord AR, Shanks GD, Edstein MD
  Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers. Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e01441-19. doi: 10.1128/AAC.01441-19. Print 2020 Feb 21.
•   Aronson NE, Sanders JW, Moran KA
  In harm's way: infections in deployed American military forces. Clin Infect Dis. 2006 Oct 15;43(8):1045-51. Epub 2006 Sep 14. Erratum in: Clin Infect Dis. 2006 Dec 1;43(11):1498.
•   Ashley EA, Pyae Phyo A, Woodrow CJ
  Malaria. Lancet. 2018 Apr 21;391(10130):1608-1621. doi: 10.1016/S0140-6736(18)30324-6. Epub 2018 Apr 6. Review.
•   Baird JK
  Tafenoquine for travelers' malaria: evidence, rationale and recommendations. J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.
•   Barrett O Jr, Skrzypek G, Datel W, Goldstein JD
  Malaria imported to the United States from Vietnam. Chemoprophylaxis evaluated in returning soldiers. Am J Trop Med Hyg. 1969 Jul;18(4):495-9.
•   Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW
  Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019 Jul 27;394(10195):332-343. doi: 10.1016/S0140-6736(19)31096-7. Epub 2019 Jun 19.
•   BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J
  An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.
•   Beck HP, Wampfler R, Carter N, Koh G, Osorio L, Rueangweerayut R, Krudsood S, Lacerda MV, Llanos-Cuentas A, Duparc S, Rubio JP, Green JA
  Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. J Infect Dis. 2016 Mar 1;213(5):794-9. doi: 10.1093/infdis/jiv508. Epub 2015 Oct 23.
•   Bellanger AP, Faucher JF, Robedat P, Schmitt A, Millon L, Hoen B
  Malaria outbreak in French troops returning from Côte d'Ivoire. Scand J Infect Dis. 2011 Mar;43(3):230-3. doi: 10.3109/00365548.2010.538857. Epub 2010 Nov 25.
•   Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF
  Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013 Oct 3;369(14):1381-2. doi: 10.1056/NEJMc1301936.
•   Brisson M, Brisson P
  Compliance with antimalaria chemoprophylaxis in a combat zone. Am J Trop Med Hyg. 2012 Apr;86(4):587-90. doi: 10.4269/ajtmh.2012.11-0511.
•   Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD
  Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother. 2007 Aug;51(8):2709-15. Epub 2007 May 21.
•   Chu CS, Freedman DO
  Tafenoquine and G6PD: a primer for clinicians. J Travel Med. 2019 Jun 1;26(4). pii: taz023. doi: 10.1093/jtm/taz023. Review.
•   Chua ACY, Ong JJY, Malleret B, Suwanarusk R, Kosaisavee V, Zeeman AM, Cooper CA, Tan KSW, Zhang R, Tan BH, Abas SN, Yip A, Elliot A, Joyner CJ, Cho JS, Breyer K, Baran S, Lange A, Maher SP, Nosten F, Bodenreider C, Yeung BKS, Mazier D, Galinski MR, Dereuddre-Bosquet N, Le Grand R, Kocken CHM, Rénia L, Kyle DE, Diagana TT, Snounou G, Russell B, Bifani P
  Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. Nat Commun. 2019 Aug 12;10(1):3635. doi: 10.1038/s41467-019-11332-4.
•   Coleman RE, Clavin AM, Milhous WK
  Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg. 1992 Feb;46(2):169-82.
•   Coleman RE
  Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi. Am J Trop Med Hyg. 1990 Mar;42(3):196-205.
•   Commons RJ, McCarthy JS, Price RN
  Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020 Mar;212(4):152-153.e1. doi: 10.5694/mja2.50474. Epub 2020 Feb 9.
•   Daher A, Aljayyoussi G, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, Alves JC, da Fonseca LB, da Silva DMD, Pinto DP, Rodrigues DF, Silvino ACR, de Sousa TN, de Brito CFA, Ter Kuile FO, Lalloo DG
  Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine. Malar J. 2019 Sep 23;18(1):325. doi: 10.1186/s12936-019-2950-4.
•   Douglas AD, Baldeviano GC, Jin J, Miura K, Diouf A, Zenonos ZA, Ventocilla JA, Silk SE, Marshall JM, Alanine DGW, Wang C, Edwards NJ, Leiva KP, Gomez-Puerta LA, Lucas CM, Wright GJ, Long CA, Royal JM, Draper SJ
  A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates. Nat Commun. 2019 Apr 26;10(1):1953. doi: 10.1038/s41467-019-09894-4.
•   Dow G, Smith B
  The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). Malar J. 2017 May 19;16(1):209. doi: 10.1186/s12936-017-1862-4. Review.
•   Dow GS, Liu J, Lin G, Hetzell B, Thieling S, McCarthy WF, Tang D, Smith B
  Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Malar J. 2015 Nov 26;14:473. doi: 10.1186/s12936-015-0991-x.
•   Dow GS, McCarthy WF, Reid M, Smith B, Tang D, Shanks GD
  A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area. Malar J. 2014 Feb 6;13:49. doi: 10.1186/1475-2875-13-49.
•   Eastman RT, Fidock DA
  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009 Dec;7(12):864-74. doi: 10.1038/nrmicro2239. Epub 2009 Nov 2. Review.
•   Ebstie YA, Abay SM, Tadesse WT, Ejigu DA
  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016. Review.
•   Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG
  Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001 Dec;52(6):663-70.
•   Edstein MD, Kocisko DA, Walsh DS, Eamsila C, Charles BG, Rieckmann KH
  Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis. Clin Infect Dis. 2003 Dec 15;37(12):1654-8. Epub 2003 Nov 20.
•   Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL
  Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members. Am J Trop Med Hyg. 2017 Jan 11;96(1):159-166. doi: 10.4269/ajtmh.16-0390. Epub 2016 Nov 14.
•   Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD
  The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1095-101. doi: 10.1016/j.trstmh.2008.04.024. Epub 2008 Jun 9.
•   Fernando SD, Ranaweera D, Weerasena MS, Booso R, Wickramasekara T, Madurapperuma CP, Danansuriya M, Rodrigo C, Herath H
  Success of malaria chemoprophylaxis for outbound civil and military travellers in prevention of reintroduction of malaria in Sri Lanka. Int Health. 2020 Jul 1;12(4):332-338. doi: 10.1093/inthealth/ihz094.
•   Frampton JE
  Tafenoquine: First Global Approval. Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2. Review.
•   Fry M, Pudney M
  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992 Apr 1;43(7):1545-53.
•   Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C
  A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS One. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.
•   Fukuda MM, Wojnarski M, Martin N, Zottig V, Waters NC
  Editorial: Malaria in the Korean peninsula: Risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon. MSMR. 2018 Nov;25(11):2-3.
•   Green JA, Patel AK, Patel BR, Hussaini A, Harrell EJ, McDonald MJ, Carter N, Mohamed K, Duparc S, Miller AK
  Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol. 2014 Sep;54(9):995-1005. doi: 10.1002/jcph.302. Epub 2014 Apr 9.
•   Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL
  A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003 Mar 1;36(5):541-9. Epub 2003 Feb 14.
•   Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, Hien TT, Hongvanthong B, Chindavongsa K, Mayxay M, Huy R, Leang R, Huch C, Dysoley L, Amaratunga C, Suon S, Fairhurst RM, Tripura R, Peto TJ, Sovann Y, Jittamala P, Hanboonkunupakarn B, Pukrittayakamee S, Chau NH, Imwong M, Dhorda M, Vongpromek R, Chan XHS, Maude RJ, Pearson RD, Nguyen T, Rockett K, Drury E, Gonçalves S, White NJ, Day NP, Kwiatkowski DP, Dondorp AM, Miotto O
  Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect Dis. 2019 Sep;19(9):943-951. doi: 10.1016/S1473-3099(19)30392-5. Epub 2019 Jul 22.
•   Happi CT, Gbotosho GO, Folarin OA, Milner D, Sarr O, Sowunmi A, Kyle DE, Milhous WK, Wirth DF, Oduola AM
  Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J. 2006 Oct 4;5:82.
•   Hounkpatin AB, Kreidenweiss A, Held J
  Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. Infect Drug Resist. 2019 Mar 6;12:553-570. doi: 10.2147/IDR.S151031. eCollection 2019. Review.
•   Klein TA, Seyoum B, Forshey BM, Ellis KK, McCall H, Jackson K, Tucker C, Yi S, Kim M, Kim H
  Cluster of vivax malaria in U.S. soldiers training near the demilitarized zone, Republic of Korea during 2015. MSMR. 2018 Nov;25(11):4-9.
•   Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q
  Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000 Aug;44(8):2100-8.
•   Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, Yilma D, Batista Pereira D, Espino FEJ, Mia RZ, Chuquiyauri R, Val F, Casapía M, Monteiro WM, Brito MAM, Costa MRF, Buathong N, Noedl H, Diro E, Getie S, Wubie KM, Abdissa A, Zeynudin A, Abebe C, Tada MS, Brand F, Beck HP, Angus B, Duparc S, Kleim JP, Kellam LM, Rousell VM, Jones SW, Hardaker E, Mohamed K, Clover DD, Fletcher K, Breton JJ, Ugwuegbulam CO, Green JA, Koh GCKW
  Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.
•   Lalani T, Yun H, Tribble D, Ganesan A, Kunz A, Fairchok M, Schnaubelt E, Fraser J, Mitra I, Kronmann KC, Burgess T, Deiss RG, Riddle MS, Johnson MD
  A comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic for Plasmodium falciparum malaria. J Travel Med. 2016 Jul 4;23(5). doi: 10.1093/jtm/taw043. Print 2016 May.
•   Landman KZ, Tan KR, Arguin PM
  Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013. Travel Med Infect Dis. 2015 Jan-Feb;13(1):61-8. doi: 10.1016/j.tmaid.2014.12.001. Epub 2014 Dec 11.
•   Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L
  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.
•   Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F, Monteiro WM, Brito MAM, Costa MRF, Chuquiyauri R, Casapía M, Nguyen CH, Aruachan S, Papwijitsil R, Nosten FH, Bancone G, Angus B, Duparc S, Craig G, Rousell VM, Jones SW, Hardaker E, Clover DD, Kendall L, Mohamed K, Koh GCKW, Wilches VM, Breton JJ, Green JA
  Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.
•   Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, Tarning J
  Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother. 2014 Jul;58(7):3889-94. doi: 10.1128/AAC.02362-14. Epub 2014 Apr 28.
•   McCarthy JS, Smith B, Reid M, Berman J, Marquart L, Dobbin C, West L, Read LT, Dow GS
  Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study. Clin Infect Dis. 2019 Jul 18;69(3):480-486. doi: 10.1093/cid/ciy939.
•   Nasveld P, Kitchener S
  Treatment of acute vivax malaria with tafenoquine. Trans R Soc Trop Med Hyg. 2005 Jan;99(1):2-5.
•   Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W; Tafenoquine Study Team
  Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7.
•   Newton JA Jr, Schnepf GA, Wallace MR, Lobel HO, Kennedy CA, Oldfield EC 3rd
  Malaria in US Marines returning from Somalia. JAMA. 1994 Aug 3;272(5):397-9.
•   Nicolas B, Papillault des Charbonnières L, Vasseur T, Mauclere P
  Assessment of adherence to malaria chemoprophylaxis in a French Navy frigate deployed in Southeast Asia. Med Sante Trop. 2017 Jun 1;27(2):155-159. doi: 10.1684/mst.2017.0666.
•   Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S
  Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis. Travel Med Infect Dis. 2017 May - Jun;17:19-27. doi: 10.1016/j.tmaid.2017.05.008. Epub 2017 May 8.
•   Pang LW, Limsomwong N, Boudreau EF, Singharaj P
  Doxycycline prophylaxis for falciparum malaria. Lancet. 1987 May 23;1(8543):1161-4.
•   Petersen E
  The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. J Travel Med. 2003 May;10 Suppl 1:S13-5; discussion S21.
•   Plucinski MM, Huber CS, Akinyi S, Dalton W, Eschete M, Grady K, Silva-Flannery L, Mathison BA, Udhayakumar V, Arguin PM, Barnwell JW
  Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in Nigeria. Open Forum Infect Dis. 2014 Aug 5;1(2):ofu059. doi: 10.1093/ofid/ofu059. eCollection 2014 Sep.
•   Ponsa N, Sattabongkot J, Kittayapong P, Eikarat N, Coleman RE
  Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg. 2003 Nov;69(5):542-7.
•   Quang NN, Chavchich M, Anh CX, Birrell GW, van Breda K, Travers T, Rowcliffe K, Edstein MD
  Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate-Amodiaquine and Artemisinin-Piperaquine in Healthy Volunteers for Preselection Malaria Therapy. Am J Trop Med Hyg. 2018 Jul;99(1):65-72. doi: 10.4269/ajtmh.17-0434. Epub 2018 May 3.
•   Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C
  Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J. 2009 Jan 12;8:10. doi: 10.1186/1475-2875-8-10.
•   Rutherford AE, Yale RS, Finn MF
  Malaria Prophylaxis Adherence Among Aircrew Members. Aerosp Med Hum Perform. 2019 Jul 1;90(7):643-646. doi: 10.3357/AMHP.5306.2019.
•   Saunders D, Duplessis C, Lescano A, Andagalu B, Thomas A, Fukuda M, Cummings J; US DoD Malaria Surveillance Investigators Group
  US Department of Defense contributions to malaria surveillance. Lancet Infect Dis. 2013 Apr;13(4):293-4. doi: 10.1016/S1473-3099(13)70065-3.
•   Saunders DL, Garges E, Manning JE, Bennett K, Schaffer S, Kosmowski AJ, Magill AJ
  Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan. Am J Trop Med Hyg. 2015 Sep;93(3):584-90. doi: 10.4269/ajtmh.15-0245. Epub 2015 Jun 29.
•   Schneiderman AI, Cypel YS, Dursa EK, Bossarte RM
  Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the Wars in Iraq and Afghanistan. Am J Trop Med Hyg. 2018 Sep;99(3):638-648. doi: 10.4269/ajtmh.18-0107. Epub 2018 Jun 21.
•   Schwartz E
  Prophylaxis of malaria. Mediterr J Hematol Infect Dis. 2012;4(1):e2012045. doi: 10.4084/MJHID.2012.45. Epub 2012 Jun 29.
•   Shah NK, Alker AP, Sem R, Susanti AI, Muth S, Maguire JD, Duong S, Ariey F, Meshnick SR, Wongsrichanalai C
  Molecular surveillance for multidrug-resistant Plasmodium falciparum, Cambodia. Emerg Infect Dis. 2008 Oct;14(10):1637-40. doi: 10.3201/eid1410.080080.
•   Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R
  A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001 Dec 15;33(12):1968-74. Epub 2001 Nov 7.
•   Spring MD, Sousa JC, Li Q, Darko CA, Morrison MN, Marcsisin SR, Mills KT, Potter BM, Paolino KM, Twomey PS, Moon JE, Tosh DM, Cicatelli SB, Froude JW, Pybus BS, Oliver TG, McCarthy WF, Waters NC, Smith PL, Reichard GA, Bennett JW
  Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. J Infect Dis. 2019 Oct 22;220(11):1761-1770. doi: 10.1093/infdis/jiz386. Erratum in: J Infect Dis. 2020 Mar 16;221(7):1204.
•   St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, Beaumont C, Llanos-Cuentas A, Rueangweerayut R, Krudsood S, Green JA, Rubio JP
  Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J. 2016 Feb 18;15:97. doi: 10.1186/s12936-016-1145-5.
•   Terrell AG, Forde ME, Firth R, Ross DA
  Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline. J Travel Med. 2015 Nov-Dec;22(6):383-8. doi: 10.1111/jtm.12232. Epub 2015 Oct 1.
•   Thakkar N, Green JA, Koh GCKW, Duparc S, Tenero D, Goyal N
  Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial. Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00711-18. doi: 10.1128/AAC.00711-18. Print 2018 Nov.
•   Vinayak S, Alam MT, Sem R, Shah NK, Susanti AI, Lim P, Muth S, Maguire JD, Rogers WO, Fandeur T, Barnwell JW, Escalante AA, Wongsrichanalai C, Ariey F, Meshnick SR, Udhayakumar V
  Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J Infect Dis. 2010 May 15;201(10):1551-60. doi: 10.1086/651949.
•   Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG
  Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J Infect Dis. 2004 Oct 15;190(8):1456-63. Epub 2004 Sep 20.
•   Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP
  Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis. 1999 Oct;180(4):1282-7.
•   Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S
  Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004 Oct 15;39(8):1095-103. Epub 2004 Sep 24.
•   Warrasak S, Euswas A, Fukuda MM, Ittiverakul M, Miller RS, Krudsood S, Ohrt C
  Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. Int Ophthalmol. 2019 Aug;39(8):1767-1782. doi: 10.1007/s10792-018-1003-2. Epub 2018 Sep 29.
•   Wellems TE, Plowe CV
  Chloroquine-resistant malaria. J Infect Dis. 2001 Sep 15;184(6):770-6. Epub 2001 Aug 7. Review.
•   Whitman TJ, Coyne PE, Magill AJ, Blazes DL, Green MD, Milhous WK, Burgess TH, Freilich D, Tasker SA, Azar RG, Endy TP, Clagett CD, Deye GA, Shanks GD, Martin GJ
  An outbreak of Plasmodium falciparum malaria in U.S. Marines deployed to Liberia. Am J Trop Med Hyg. 2010 Aug;83(2):258-65. doi: 10.4269/ajtmh.2010.09-0774.
•   Wojnarski M, Lon C, Vanachayangkul P, Gosi P, Sok S, Rachmat A, Harrison D, Berjohn CM, Spring M, Chaoratanakawee S, Ittiverakul M, Buathong N, Chann S, Wongarunkochakorn S, Waltmann A, Kuntawunginn W, Fukuda MM, Burkly H, Heang V, Heng TK, Kong N, Boonchan T, Chum B, Smith P, Vaughn A, Prom S, Lin J, Lek D, Saunders D
  Atovaquone-Proguanil in Combination With Artesunate to Treat Multidrug-Resistant P. falciparum Malaria in Cambodia: An Open-Label Randomized Trial. Open Forum Infect Dis. 2019 Sep 4;6(9):ofz314. doi: 10.1093/ofid/ofz314. eCollection 2019 Sep.
•   Woodrow CJ, White NJ
  The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017 Jan;41(1):34-48. doi: 10.1093/femsre/fuw037. Epub 2016 Sep 8. Review.

Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers

Details for clinical trial NCT05203744